Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study Says No To Angioplasty Days After A Heart Attack

This article was originally published in The Gray Sheet

Executive Summary

A study presented at an American Heart Association (AHA) conference last week concludes that angioplasty and stenting are of no value to heart attack patients if used three days or later following the event, even if the impacted artery remains blocked

You may also be interested in...



More Stent Scrutiny: Many PCIs Are Performed More Than 24-Hours Post-MI, Despite Guidelines

Many physicians are flouting 2007 guidelines to not stent stable heart disease patients with completely blocked arteries more than 24 hours after a myocardial infarction, according to a registry analysis published July 11.

More Stent Scrutiny: Many PCIs Are Performed More Than 24-Hours Post-MI, Despite Guidelines

Many physicians are flouting 2007 guidelines to not stent stable heart disease patients with completely blocked arteries more than 24 hours after a myocardial infarction, according to a registry analysis published July 11.

Thrombosis Risk In Taxus And Cypher Is Real, TCT Data Shows; Now What?

With a growing consensus coming out of last week's Transcatheter Cardiovascular Therapeutics meeting that first-generation drug-eluting stents (DES) are associated with an increased long-term risk of blood clots, cardiologists are grappling with how use of these blockbuster products might need to be modified

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel